Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA)…
Read More...
Read More...